Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Qiagen ( (QGEN) ) just unveiled an update.
On January 31, 2025, QIAGEN N.V. announced a managers’ transaction related to a synthetic share repurchase plan. This plan, approved by shareholders in June 2024, consolidated every 36 issued QIAGEN shares into 35, affecting the holdings of managing body member Thierry Bernard, whose shares were reduced by 8,919 to a total of 312,125 common shares. This move is part of QIAGEN’s strategic financial adjustments aimed at optimizing share value and company capitalization.
More about Qiagen
QIAGEN N.V. operates in the biotechnology sector, specializing in the development and distribution of sample and assay technologies for molecular diagnostics and applied testing. The company focuses on providing innovative solutions for research in life sciences, molecular diagnostics, and other fields, catering to a global market.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.
